Eugenol alleviated nonalcoholic fatty liver disease in rat via a gut-brain-liver axis involving glucagon-like Peptide-1.

Eugenol, an active ingredient of many medicinal aromatic plants, has been proved to have the hypolipidemic effect, but its potential mechanism of action is still unknown. This study aimed to investigate whether eugenol regulates liver lipid accumulation in high-fat diet (HFD) induced nonalcoholic fatty liver disease (NAFLD) rats via the gut-brain-liver axis involving glucagon-like peptide-1 (GLP-1). Hepatic vagotomy was performed in NAFLD rats to determine the role of eugenol in regulating hepatic lipid accumulation via vagus nerve. The results showed that after eight weeks of eugenol administration in NAFLD rats, serum total cholesterol (TC), triglyceride (TG) and hepatic TG decreased. However, eugenol showed no significant effect on the increased food intakes and weight gain caused by the HFD. Eugenol promoted the secretion of GLP-1 into the blood, increased GLP-1 receptor (GLP-1R) expression in the duodenum, liver, arcuate nucleus (ARC) and paraventricular nucleus (PVN), increased c-fos expression in the nucleus tractus solitarii (NTS), and promoted ZO-1 and occludin expression in duodenum. Furthermore, steatosis and lipid accumulation were significantly alleviated. Hepatic vagotomy partially attenuated the improvement of eugenol in hepatic lipid accumulation in NAFLD rats. In conclusion, eugenol regulates hepatic lipid metabolism via a gut-brain-liver axis involving in GLP-1, providing a new strategy for the treatment of NAFLD.

• Publication year

  2022

• Venue

  Archives of Biochemistry and Biophysics

• Publication date

  2022-05-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.abb.2022.109269PMID 35508252
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Asian perspective on NAFLD-associated HCC.

  2021cited by this paper
• Application of Machine Learning for Drug–Target Interaction Prediction

  2021cited by this paper
• NAFLD 2020: The State of the Disease.

  2020cited by this paper
• Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain

  2020cited by this paper
• Machine learning approaches and databases for prediction of drug–target interaction: a survey paper

  2020cited by this paper
• Incretins in obesity and diabetes

  2020cited by this paper
• Anti-obesity effects of Spirulina platensis protein hydrolysate by modulating brain-liver axis in high-fat diet fed mice

  2019cited by this paper
• Eugenol Reduces LDL Cholesterol and Hepatic Steatosis in Hypercholesterolemic Rats by Modulating TRPV1 Receptor

  2019cited by this paper
• Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.

  2019cited by this paper
• Eugenol ameliorates insulin resistance, oxidative stress and inflammation in high fat‐diet/streptozotocin‐induced diabetic rat

  2019cited by this paper
• Modulation of inducible nitric oxide synthase pathway by eugenol and telmisartan in carbon tetrachloride‐induced liver injury in rats

  2019cited by this paper
• From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy

  2019cited by this paper
• Intestinal Fructose and Glucose Metabolism in Health and Disease

  2019cited by this paper
• Mesenteric adipose tissue contributes to intestinal barrier integrity and protects against nonalcoholic fatty liver disease in mice.

  2018cited by this paper
• Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis

  2018cited by this paper
• Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy.

  2018cited by this paper
• Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats

  2017cited by this paper
• Pharmacological and Toxicological Properties of Eugenol

  2017cited by this paper
• Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.

  2017cited by this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cited by this paper
• Epidemiology and natural history of non-alcoholic fatty liver disease.

  2016cited by this paper
• Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway

  2016cited by this paper
• Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance.

  2016cited by this paper
• Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease: Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

  2016cited by this paper
• Non-alcoholic fatty liver disease in 2015.

  2015cited by this paper
• GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond

  2015cited by this paper
• GLP-1 based therapeutics: simultaneously combating T2DM and obesity

  2015cited by this paper
• Phytonutrient diet supplementation promotes beneficial Clostridia species and intestinal mucus secretion resulting in protection against enteric infection

  2015cited by this paper
• Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats

  2015cited by this paper
• Differential effects of eugenol against hepatic inflammation and overall damage induced by ischemia/re-perfusion injury

  2014cited by this paper
• Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway.

  2014cited by this paper
• Gut microbiota and GLP-1

  2014cited by this paper
• Impact of the hepatic branch of the vagus and Roux-en-Y gastric bypass on the hypoglycemic effect and glucagon-like peptide-1 in rats with type 2 diabetes mellitus.

  2014cited by this paper
• Ameliorating effect of eugenol on hyperglycemia by attenuating the key enzymes of glucose metabolism in streptozotocin-induced diabetic rats

  2013cited by this paper
• Gut microbiota and non-alcoholic fatty liver disease: new insights.

  2013cited by this paper
• Obesity and Appetite Control

  2012cited by this paper
• Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis

  2012cited by this paper
• Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.

  2012cited by this paper
• Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic

  2012cited by this paper
• Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample

  2010cited by this paper
• Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats.

  2010cited by this paper
• Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides.

  2010cited by this paper
• Eugenol precludes cutaneous chemical carcinogenesis in mouse by preventing oxidative stress and inflammation and by inducing apoptosis

  2010cited by this paper
• The gut‐brain‐liver axis: A new option to treat obesity and diabetes?

  2008cited by this paper
• The hypothalamic arcuate nucleus: a key site for mediating leptin's effects on glucose homeostasis and locomotor activity.

  2005cited by this paper
• Cardiovascular Effects of Eugenol, a Phenolic Compound Present in Many Plant Essential Oils, in Normotensive Rats

  2004cited by this paper
• Hypothalamic insulin signaling is required for inhibition of glucose production

  2002cited by this paper
• The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis

  2001cited by this paper
• Effect of mesenteric ischemia and reperfusion or hemorrhagic shock on intestinal mucosal permeability and ATP content in rats.

  1999cited by this paper
• International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease

  year unknowncited by this paper
• Nonalcoholic Fatty LiverDisease Diagnosis Treatment Practice Improvement Nonalcoholic fatty liver disease ( NAFLD ) is theleading causeof chronic liver disease

  year unknowncited by this paper

• Research progress on the role and mechanism of traditional Chinese medicine based on "liver-multiple-organ interaction".

  2026cites this paper
• Protective effects of seed oil from Nicotiana tabacum L. On D-galactose induced liver and brain damages of mice by regulating PI3K/Akt/Nrf2 signaling pathway

  2025cites this paper
• Cardiovascular protective properties of the natural product eugenol.

  2025cites this paper
• Dietary supplementation with eugenol modulates lipid metabolism in finishing pigs through the TRPV1/AMPK signaling pathway.

  2025cites this paper
• Nicotinamide N-Methyltransferase in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights and Emerging Therapeutic Strategies.

  2025cites this paper
• Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects

  2025cites this paper
• Syzygium aromaticum L. (Clove): A Comprehensive Reveiw of Its Ethnopharmacological Uses and Pharmacological Activities

  2025cites this paper
• L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism

  2024cites this paper
• The gut-liver axis in fatty liver disease: role played by natural products.

  2024cites this paper
• Preparation, characterization, oral bioavailability, and pharmacodynamic study of eugenol-porous silica solidified powder

  2024cites this paper
• Natural Products in Non-alcoholic Fatty Liver Disease (NAFLD): Novel lead discovery for drug development.

  2023cites this paper
• An Update on the Therapeutic Anticancer Potential of Ocimum sanctum L.: “Elixir of Life”

  2023cites this paper
• Gut microbiota–mitochondrial inter-talk in non-alcoholic fatty liver disease

  2022cites this paper
• Extraction of raspberry ketone from red raspberry and its intervention in the non-alcoholic fatty liver disease

  2022cites this paper